PDC LINE PHARMA
Primary tabs
About your organization / profile
PDC*line Pharma is a spin-off of the French Blood Bank (EFS) that develops immuno-oncology drugs: a new class of antitumor CD8+ T-cells inducers based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line) preloaded with target tumor antigens (shared or personalized).
The original features and mechanism of action of PDC*line overcomes the key challenges faced by conventional approaches, as it is both:
- off-the-shelf and highly scalable,
- much more potent to prime and boost an antitumor CD8+ T cell response, including with neo-antigens.
An even higher antitumor CD8+ T cell response can be obtained by multiple injections (as PDC*line is not subject to allogeneic rejection), and by co-administration with anti-PD-1 (preclinical data).
Our patented platform is also very versatile, allowing the rapid development of new candidates and genetic modifications.
Based on a positive first-in-human feasibility study completed in melanoma, we are initiating a Phase I/II proof-of-concept clinical study in lung cancer in combination with anti-PD-1
Network (0)
There are no organizations in the network.
